Sandoz, Apotex And Taro Strike Civil Settlements On Price-Fixing

Further Settlements Worth A Total Of $447m Reached By Three Firms In US

Three civil settlements worth more than $447m in total have been reached with the US Department of Justice by Sandoz, Apotex and Sun’s Taro to resolve allegations over price-fixing. The deals follow criminal penalties previously paid by the three companies.

Department of Justice
The DoJ has announced three settlements worth more than $447m • Source: Shutterstock

Sandoz, Apotex and Sun’s Taro have agreed three civil settlements worth $447.2m in total with the US Department of Justice to resolve allegations over conspiracies to fix the prices of generic drugs.

The deals come after the three companies agreed to pay criminal penalties as part of deferred prosecution agreements with the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

ADHD

This is regarding ADHD.

GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

 
• By 

In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

MPP Finds Three More Partners On Key Hepatitis C Treatment

 
• By 

The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

 
• By 

Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.